Transforming PK analysis workflows with Aplos Analytics’ upgraded platform
Aplos Analytics (UT, USA) has announced major upgrades to its cloud-based platform, Aplos NCA, offering custom data processing, flexible reporting and greater automation.
PK professionals can now look forward to a more streamlined and customizable analysis experience. Aplos Analytics has revealed significant enhancements to its Aplos NCA platform, aiming to deliver a true end-to-end solution for PK reporting, data processing and visualization, all within a secure cloud environment. The upgrade will streamline PK workflows by reducing manual steps, improving data integrity and enabling faster, more precise insights across the drug development lifecycle.
Accurate and efficient PK analysis is fundamental to drug discovery and development, impacting decisions from preclinical stages through to clinical trials. However, the process has often been hampered by fragmented tools and manual workflows. For the bioanalytical and broader scientific community, innovations that reduce bottlenecks, improve compliance and promote data-driven decisions are critical.
You may also be interested in:
- From lab to launch: strategies for scalable and compliant drug development with Lenora Dieyi
- Cross-validation of pharmacokinetic assays post-ICH M10 is not a pass/fail criterion
- Accelerating PK and ADA bioanalytical assay development
Originally launched in July 2024, Aplos NCA was promoted to the market based on its speed, simplicity and regulatory readiness. The new expansion will allow users to apply custom data processing rules, design flexible tables and figures, and generate tailored reports using personalized templates. Scientists will be able to automate common tasks like handling below the limit of quantification (BLQ) values, creating additional dataset columns and calculating within-subject ratios, all while maintaining full control over formatting and output.
Built for the modern scientist, Aplos NCA combines robust audit trails, version control and seamless integration with R, SAS and GraphPad Prism, while ensuring full compliance with global regulatory standards like the US FDA (MD, USA) 21 CFR Part 11. The PK parameters are also accepted by the EMA (Amsterdam, The Netherlands), PMDA (Tokyo, Japan) and MHRA (London, UK).
As these enhancements roll out, Aplos Analytics is set to transform how PK professionals manage and report data—empowering faster, more accurate decision-making across drug development pipelines. By reducing manual effort and boosting automation, Aplos NCA enables scientists to focus more on innovation and strategy, setting a new benchmark for the future of pharmacokinetic analysis.
